ReviewBioengineering

Cancer Nanomedicine: From Drug Delivery to Imaging

Science Translational Medicine  18 Dec 2013:
Vol. 5, Issue 216, pp. 216rv4
DOI: 10.1126/scitranslmed.3005872

You are currently viewing the abstract.

View Full Text

Log in


Abstract

Nanotechnology-based chemotherapeutics and imaging agents represent a new era of “cancer nanomedicine” working to deliver versatile payloads with favorable pharmacokinetics and capitalize on molecular and cellular targeting for enhanced specificity, efficacy, and safety. Despite the versatility of many nanomedicine-based platforms, translating new drug or imaging agents to the clinic is costly and often hampered by regulatory hurdles. Therefore, translating cancer nanomedicine may largely be application-defined, where materials are adapted only toward specific indications where their properties confer unique advantages. This strategy may also realize therapies that can optimize clinical impact through combinatorial nanomedicine. In this review, we discuss how particular materials lend themselves to specific applications, the progress to date in clinical translation of nanomedicine, and promising approaches that may catalyze clinical acceptance of nano.

View Full Text